Apimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarter - APUS News | RalliesApimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarter
A
APUS• Quarterly loss widens on digital-asset and settlement costs
- Apimeds posted a net loss of $20.17 million for the quarter ended June 30, 2026, widening from $2.66 million.
- Loss per share widened to $11.77 from $2.57.
- Other expense swung to $13.89 million from other income of $1,711, driven by a $13.18 million unrealized digital-asset loss.
- General and administrative costs jumped to $5.32 million from $2.01 million, on settlement-related fees and transaction costs.
- Research and development expenses rose 47% to $959,742 from the year-ago quarter.
Digital assets remain the main asset and source of volatility
- Digital assets had a fair value of $116.74 million, representing 89% of total assets.
- The company said earnings volatility is tied to fair-value changes in those digital assets.
